Mental health funding lacks transparency

9% of the population of Australia is taking psychiatric drugs, 5% are on antidepressants. In USA 6% are on antipsychotics making them the most commonly prescribed drugs but information on our percentages is not available in Australia. About 1% of the population suffers from schizophrenia, http://www.schizophrenia.com/szfacts.htm 0.5% to1% from bipolar http://en.wikipedia.org/wiki/Bipolar_disorder (found by the WHO's epidemiological studies over scores of years and across cultures) and biological depression is rare and treatable. 40% of these tiny percentages of persons who do suffer from genuine schizophrenia or bipolar also have genetic mutations: they are hard to treat and require close monitoring with special care. The small number of persons being treated for mental illness diagnosed and confirmed before medication, comprise a tiny minority of those I see. It is the population with side effects that manifest as the huge increase in demand (and costs) since the first of the new generation drugs, Prozac, was introduced in 1990. An adverse response to the first drug or illicit substance should suggest that the patient might have a diminishing metabolism genetic polymorphism. This information can be gained, in retrospect, by taking a good history and a buccal swab. This problem is the outcome of the education of psychiatrists by the pharmaceutical industry, which fund key opinion leaders, guideline writers, beyondblue, Lifeblood, Sphere all organisations that provide psychiatric education that serves their commercial interests and are all funded by the Pharma Collaboration. This is in conflict with the altruism, the need to put patients first, that one associates with the practice of medicine and is in the realms of the unthinkable. http://www.theage.com.au/news/national/mental-health-takes-industry-pills/2006/08/07/1154802820416.html http://www.mhca.org.au/index.php/our-work/mhcapharma-collaboration Drug-company-funded Key Opinion Leaders write tomes on “intractable schizophrenia.” The relationship of drug side effects and genes shows that most persons so diagnosed are suffering from side effects, and only a few from side effects superimposed on pre-existing mental illness. www.trsconsensus.com.au Mental illness should first be diagnosed before treatment that has similar side effects is introduced. This also accounts for deteriorating outcomes in serious (read medicated) mental illness. The evidence from epidemiologists is that the death rate and suicide rate (and violence) have increased hugely for treated serious mental illness and are 20 times as high now as they were before we started medicating willy-nilly with no regard for genetics. I quote again from Akathisia Homicides http://www.dovepress.com/articles.php?article_id=7993. "Deteriorating outcomes in mental illness, deaths, violence, and suicide rates have been documented by epidemiologists and have increased up to 20-fold since 1924. http://bjp.rcpsych.org/content/188/3/223.long http://www.ncbi.nlm.nih.gov/pubmed/21172095 http://www.ncbi.nlm.nih.gov/pubmed?term=Do%20nations’%20mental%20health%20policies%2C%20programs%20and%20legislation%20influence%20their%20suicide%20rates http://www.arafmi.org/resource/tracking-tragedy-report-homicide-serious-injury-and-suicide-2008 http://www.epi.msu.edu/janthony/EpidemiologyReviewsPathopsychology/McGrath2008.pdf Some people taking psychiatric drugs develop akathisia and some people who develop akathisia kill themselves or others. Yet the drugs can be effective in persons suffering serious depression, provided their doses are adjusted according to their ability to metabolise them normally and there is informed monitoring.
http://www.mjainsight.com.au/view?post=mental-health-funding-lacks-transparency&post_id=7889&cat=issue-3-30-january-2012